Connections between vascular calcification and progression of chronic kidney disease: Therapeutic alternatives  Keith A. Hruska, Suresh Mathew, Matthew.

Slides:



Advertisements
Similar presentations
Volume 68, Pages S24-S28 (July 2005)
Advertisements

Volume 69, Issue 1, Pages (January 2006)
Volume 79, Pages S3-S8 (April 2011)
Pleiotropic effects of the non-calcium phosphate binder sevelamer
A.M. Thompson, T.G. Pickering  Kidney International 
Fig. 1 Changes in biochemical assessment of CKD-MBD over time: Cy/+ rats were treated with diet only (CKD CTL), R-568, R Ca or calcium alone (Ca).
Beta blockers in the management of chronic kidney disease
Volume 67, Pages S1-S7 (June 2005)
Iron indices: What do they really mean?
Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation  Jordi Bover,
Cellular mechanisms of renal osteodystrophy
Volume 70, Issue 8, Pages (October 2006)
Anemia management in chronic kidney disease
American Journal of Kidney Diseases 
Volume 93, Issue 1, Pages (January 2018)
FGF23 or PTH: which comes first in CKD ?
Update on Nephrolithiasis: Core Curriculum 2016
Volume 61, Issue 4, Pages (April 2002)
Reassessment of the care of the patient with chronic kidney disease
Progression of renal failure and hypertensive nephrosclerosis
John P. Middleton, Patrick H. Pun  Kidney International 
Volume 79, Pages S3-S8 (April 2011)
M. Fukagawa, S. Nakanishi, J.J. Kazama  Kidney International 
Haiyan Wang, Luxia Zhang, Jicheng Lv  Kidney International 
Chapter 3: Management of progression and complications of CKD
Volume 91, Issue 2, Pages (February 2017)
Volume 85, Issue 3, Pages (March 2014)
Volume 62, Issue 2, Pages (August 2002)
Volume 79, Pages S9-S13 (April 2011)
Chapter 2: Use of iron to treat anemia in CKD
Volume 76, Pages S50-S99 (August 2009)
Volume 70, Pages S21-S25 (December 2006)
Volume 72, Issue 6, Pages (September 2007)
Volume 66, Pages S13-S17 (September 2004)
D. Batlle, P. Ramadugu, M.J. Soler  Kidney International 
A new era in phosphate binder therapy: What are the options?
Volume 85, Issue 1, Pages (January 2014)
Pleiotropic effects of the non-calcium phosphate binder sevelamer
Volume 74, Issue 3, Pages (August 2008)
Volume 70, Issue 11, Pages (December 2006)
Volume 79, Pages S20-S23 (April 2011)
Hyperphosphatemia of chronic kidney disease
The epidemiology of chronic kidney disease
Use of vitamin D in chronic kidney disease patients
Volume 91, Issue 5, Pages (May 2017)
Bisphosphonate safety and efficacy in chronic kidney disease
The calcium–phosphorus in guidelines for CKD-MBD
Volume 68, Pages S24-S28 (July 2005)
Volume 74, Pages S88-S93 (December 2008)
Role of vitamin D receptor activators on cardiovascular risk
Volume 56, Pages S31-S37 (December 1999)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Methods for guideline development
The global challenge of chronic kidney disease
A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease  S. Susan Hedayati, Venkata Yalamanchili,
Cardiovascular calcification in patients with chronic renal failure: Are we on target with this risk factor?  Peter A. Mccullough, Sandeep Soman  Kidney.
Cardio-Kidney-Damage: a unifying concept
Volume 55, Pages S3-S16 (June 1999)
Volume 80, Issue 10, Pages (November 2011)
Volume 69, Issue 1, Pages (January 2006)
Internet Organ Solicitation, Explained
Cardiovascular risk in chronic kidney disease
Charles A. Herzog  Kidney International 
Is complement a target for therapy in renal disease?
Renal vascular disease in the elderly
In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression  B.O. Eriksen, O.C. Ingebretsen  Kidney.
Volume 74, Issue 10, Pages (November 2008)
Kidney and hypertension
Decision-Making in Patients With Cancer and Kidney Disease
Presentation transcript:

Connections between vascular calcification and progression of chronic kidney disease: Therapeutic alternatives  Keith A. Hruska, Suresh Mathew, Matthew M. Davies, Richard R. Lund  Kidney International  Volume 68, Pages S142-S151 (December 2005) DOI: 10.1111/j.1523-1755.2005.09926.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Bone volume, osteoid volume, osteoclast number, osteoblast perimeter, and osteoblast number in metaphyseal trabeculae. There were no significant changes in bone volume between groups (A), although there was an osteopenic tendency in the LDLR-/- high-fat-fed CKD group. There was a significant hyperosteoidosis produced in the CKD high-fat-fed group (B), possibly related to the secondary hyperparathyroidism as expected (*P < 0.05 compared with the sham group). There were no differences in osteoclast numbers between the groups (C). Osteoblast perimeter (D) and number (E) were significantly reduced by CKD in the LDLR-/- high-fat-fed animals, and BMP-7 therapy restored osteoblast surfaces and number to normal when compared with the LDLR-/- sham chow-fed animals or with wild-type chow-fed animals. (*P < 0.05 compared with sham chow-fed LDLR-/- animals). Values represent mean ± standard deviation. Reprinted from Davies et al, J Am Soc Nephrol 16:917–928, 2005, with permission from the American Society of Nephrology. Kidney International 2005 68, S142-S151DOI: (10.1111/j.1523-1755.2005.09926.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Mineralizing surfaces, bone formation rates, and adjusted apposition rates. Mineralizing surfaces (A) were significantly decreased in the CKD high-fat-fed animals. Despite the tendency for osteoblast number and perimeter to be increased in LDLR-/- chow-fed sham animals compared with wild-type animals (Fig. 4.), the mineralizing surfaces were slightly lower and further decreased by high-fat feeding. The bone formation rates (B) were significantly decreased by high-fat feeding in both the sham and CKD groups and returned to normal by BMP-7 therapy. Reprinted from Davies et al, J Am Soc Nephrol 16:917–928, 2005, with permission from the American Society of Nephrology. Kidney International 2005 68, S142-S151DOI: (10.1111/j.1523-1755.2005.09926.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 (A) Aortic calcium levels in the various animal groups. (B) Relationship between adjusted bone apposition rates and aortic calcium content in the three groups of animals. Kidney International 2005 68, S142-S151DOI: (10.1111/j.1523-1755.2005.09926.x) Copyright © 2005 International Society of Nephrology Terms and Conditions